nach oben

World Journal of Urology

Erschienen in:

12.06.2019 | Topic Paper

A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease

verfasst von: Darshan P. Patel, Michael B. Christensen, James M. Hotaling, Alexander W. Pastuszak

Erschienen in: World Journal of Urology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Peyronie’s disease (PD) is a superficial fibrosing disorder that causes penile deformity and can interfere with sexual intercourse and reproduction, as well as diminish quality of life. While the exact mechanism of PD is still being investigated, there is likely a genetic component to the predisposition to penile plaque formation. Ultimately, however, perturbations in normal wound healing and aberrant deposition of extracellular matrix components lead to fibrotic tissue deposition. Fibrosis in PD is regulated by a complex pathway of inflammatory and fibrotic mediators. Currently there are no treatments for PD that address an underlying cause or disease progression. In this review, we provide an overview of the known inflammatory and fibrotic mediators of PD and explore the pathophysiology of other human superficial fibrosing disorders to develop further insights into PD.

Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X (2011) A population-based study of Peyronie’s disease: prevalence and treatment patterns in the United States. Adv Urol 2011:282503. https://doi.org/10.1155/2011/282503 CrossRefPubMedPubMedCentral

Stuntz M, Perlaky A, Des Vignes F, Kyriakides T, Glass D (2016) The prevalence of Peyronie’s disease in the United States: a population-based study. PLoS One 11(2):e0150157. https://doi.org/10.1371/journal.pone.0150157 CrossRefPubMedPubMedCentral

Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie’s disease: results of a large survey. BJU Int 88(7):727–730CrossRef

Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT (1991) The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 146(4):1007–1009CrossRef

Gonzalez-Cadavid NF, Rajfer J (2005) Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol 2(6):291–297. https://doi.org/10.1038/ncpuro0201 CrossRefPubMed

Nyberg LM Jr, Bias WB, Hochberg MC, Walsh PC (1982) Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 128(1):48–51CrossRef

Willscher MK, Cwazka WF, Novicki DE (1979) The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol 122(1):34–35CrossRef

Rockey DC, Bell PD, Hill JA (2015) Fibrosis—a common pathway to organ injury and failure. N Engl J Med 373(1):96. https://doi.org/10.1056/NEJMc1504848 CrossRefPubMed

Rosenbloom J, Castro SV, Jimenez SA (2010) Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152(3):159–166. https://doi.org/10.7326/0003-4819-152-3-201002020-00007 CrossRefPubMed

10.

Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X (2011) Prevalence, incidence, and treatments of Dupuytren’s disease in the United States: results from a population-based study. Hand (New York, NY) 6(2):149–158. https://doi.org/10.1007/s11552-010-9306-4 CrossRef

11.

Nugteren HM, Nijman JM, de Jong IJ, van Driel MF (2011) The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res 23(4):142–145. https://doi.org/10.1038/ijir.2011.18 CrossRefPubMed

12.

Shindel AW, Sweet G, Thieu W, Durbin-Johnson B, Rothschild J, Szabo R (2017) Prevalence of Peyronie’s disease-like symptoms in men presenting with dupuytren contractures. Sex Med 5(3):e135–e141. https://doi.org/10.1016/j.esxm.2017.06.001 CrossRefPubMedPubMedCentral

13.

Alioto RJ, Rosier RN, Burton RI, Puzas JE (1994) Comparative effects of growth factors on fibroblasts of Dupuytren’s tissue and normal palmar fascia. J Hand Surg 19(3):442–452CrossRef

14.

Badalamente MA, Hurst LC, Grandia SK, Sampson SP (1992) Platelet-derived growth factor in Dupuytren’s disease. J Hand Surg 17(2):317–323CrossRef

15.

Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K (1996) The role of transforming growth factor beta in Dupuytren’s disease. J Hand Surg 21(2):210–215. https://doi.org/10.1016/s0363-5023(96)80102-x CrossRef

16.

Bayat A, Alansar A, Hajeer AH, Shah M, Watson JS, Stanley JK, Ferguson MW, Ollier WE (2002) Genetic susceptibility in Dupuytren’s disease: lack of association of a novel transforming growth factor beta(2) polymorphism in Dupuytren’s disease. J Hand Surg (Edinburgh, Scotland) 27(1):47–49. https://doi.org/10.1054/jhsb.2001.0689 CrossRef

17.

Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D (1995) TGF beta and bFGF synthesis and localization in Dupuytren’s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 27(12):1014–1020CrossRef

18.

Gonzalez AM, Buscaglia M, Fox R, Isacchi A, Sarmientos P, Farris J, Ong M, Martineau D, Lappi DA, Baird A (1992) Basic fibroblast growth factor in Dupuytren’s contracture. Am J Pathol 141(3):661–671PubMedPubMedCentral

19.

Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF (2004) Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 64(2):399–404. https://doi.org/10.1016/j.urology.2004.04.006 CrossRefPubMed

20.

Bilgutay AN, Pastuszak AW (2015) Peyronie’s disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep 7(2):117–131. https://doi.org/10.1007/s11930-015-0045-y CrossRefPubMedPubMedCentral

21.

Kim SK, Ioannidis JPA, Ahmed MA, Avins AL, Kleimeyer JP, Fredericson M, Dragoo JL (2018) Two genetic variants associated with plantar fascial disorders. Int J Sports Med 39(4):314–321. https://doi.org/10.1055/s-0044-100280 CrossRefPubMed

22.

Dolmans GH, de Bock GH, Werker PM (2012) Dupuytren diathesis and genetic risk. J Hand Surg 37(10):2106–2111. https://doi.org/10.1016/j.jhsa.2012.07.017 CrossRef

23.

Martinez MA, Ferrando D, Cordero PJ (1997) Idiopathic pulmonary fibrosis and Peyronie’s disease. Arch Bronconeumol 33(10):549–550CrossRef

24.

Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, Krishan R, Carson CC 3rd (1997) Peyronie’s disease is associated with Paget’s disease of bone. J Bone Miner Res 12(6):929–934. https://doi.org/10.1359/jbmr.1997.12.6.929 CrossRefPubMed

25.

Akbal C, Tanidir Y, Ozgen MB, Simsek F (2008) Erectile dysfunction and Peyronie’s disease in patient with retroperitoneal fibrosis. Int Urol Nephrol 40(4):971–975. https://doi.org/10.1007/s11255-008-9381-4 CrossRefPubMed

26.

Chen TY, Zahran AR, Carrier S (2001) Penile curvature associated with scleroderma. Urology 58(2):282CrossRef

27.

Chen DL, Chong AH, Green J, Orchard D, Williams R, Clemens L (2006) A novel case of polyfibromatosis and interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol 55(2 Suppl):S32–S37. https://doi.org/10.1016/j.jaad.2006.02.038 CrossRefPubMed

28.

Simeon CP, Fonollosa V, Vilardell M, Ordi J, Solans R, Lima J (1994) Impotence and Peyronie’s disease in systemic sclerosis. Clin Exp Rheumatol 12(4):464PubMed

29.

Ordi J, Selva A, Fonollosa V, Vilardell M, Jordana R, Tolosa C (1990) Peyronie’s disease in systemic sclerosis. Ann Rheum Dis 49(2):134–135CrossRef

30.

Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, Russo A, Capitanio U, Briganti A, Cantiello F, Mirone V, Damiano R, Montorsi F, Salonia A (2015) Peyronie’s disease and autoimmunity-a real-life clinical study and comprehensive review. J Sex Med 12(4):1062–1069. https://doi.org/10.1111/jsm.12825 CrossRefPubMed

31.

Pastuszak AW, Rodriguez KM, Solomon ZJ, Kohn TP, Lipshultz LI, Eisenberg ML (2018) Increased risk of incident disease in men with Peyronie’s disease: analysis of U.S. claims data. J Sex Med 15(6):894–901. https://doi.org/10.1016/j.jsxm.2018.04.640 CrossRefPubMed

32.

Lue TF (2002) Peyronie’s disease: an anatomically-based hypothesis and beyond. Int J Impot Res 14(5):411–413. https://doi.org/10.1038/sj.ijir.3900876 CrossRefPubMed

33.

Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol 12(6):325–338. https://doi.org/10.1038/nrneph.2016.48 CrossRefPubMed

34.

Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214(2):199–210. https://doi.org/10.1002/path.2277 CrossRefPubMedPubMedCentral

35.

Border WA, Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331(19):1286–1292. https://doi.org/10.1056/nejm199411103311907 CrossRefPubMed

36.

Border WA, Ruoslahti E (1992) Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Investig 90(1):1–7. https://doi.org/10.1172/jci115821 CrossRefPubMed

37.

El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF (1997) An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 158(6):2284–2290CrossRef

38.

El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF (1997) Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158(4):1391–1394CrossRef

39.

Ryu JK, Kim WJ, Choi MJ, Park JM, Song KM, Kwon MH, Das ND, Kwon KD, Batbold D, Yin GN, Suh JK (2013) Inhibition of histone deacetylase 2 mitigates profibrotic TGF-beta1 responses in fibroblasts derived from Peyronie’s plaque. Asian J Androl 15(5):640–645. https://doi.org/10.1038/aja.2013.61 CrossRefPubMedPubMedCentral

40.

Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J (2002) Gene expression in Peyronie’s disease. Int J Impot Res 14(5):361–374. https://doi.org/10.1038/sj.ijir.3900873 CrossRefPubMed

41.

Giannandrea M, Parks WC (2014) Diverse functions of matrix metalloproteinases during fibrosis. Dis Models Mech 7(2):193–203. https://doi.org/10.1242/dmm.012062 CrossRef

42.

Pardo A, Selman M (2006) Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 3(4):383–388. https://doi.org/10.1513/pats.200601-012TK CrossRefPubMed

43.

Van de Water L (1997) Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie’s disease. J Urol 157(1):306–310CrossRef

44.

El-Sakka AI, Salabas E, Dincer M, Kadioglu A (2013) The pathophysiology of Peyronie’s disease. Arab J Urol 11(3):272–277. https://doi.org/10.1016/j.aju.2013.06.006 CrossRefPubMedPubMedCentral

45.

Moreland RB, Nehra A (2002) Pathophysiology of Peyronie’s disease. Int J Impot Res 14(5):406–410. https://doi.org/10.1038/sj.ijir.3900875 CrossRefPubMed

46.

Liu RM, Desai LP (2015) Reciprocal regulation of TGF-beta and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol 6:565–577. https://doi.org/10.1016/j.redox.2015.09.009 CrossRefPubMedPubMedCentral

47.

Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF (2005) Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. Biol Reprod 73(6):1199–1210. https://doi.org/10.1095/biolreprod.105.041038 CrossRefPubMed

48.

Huleihel M, Douvdevani A, Segal S, Apte RN (1990) Regulation of interleukin 1 generation in immune-activated fibroblasts. Eur J Immunol 20(4):731–738. https://doi.org/10.1002/eji.1830200404 CrossRefPubMed

49.

Pryor JP, Ralph DJ (2002) Clinical presentations of Peyronie’s disease. Int J Impot Res 14(5):414–417. https://doi.org/10.1038/sj.ijir.3900877 CrossRefPubMed

50.

Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M (1998) Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem 123(3):431–439CrossRef

51.

Bivalacqua TJ, Champion HC, Hellstrom WJ (2002) Implications of nitric oxide synthase isoforms in the pathophysiology of Peyronie’s disease. Int J Impot Res 14(5):345–352. https://doi.org/10.1038/sj.ijir.3900872 CrossRefPubMed

52.

Mulhall JP, Thom J, Lubrano T, Shankey TV (2001) Basic fibroblast growth factor expression in Peyronie’s disease. J Urol 165(2):419–423. https://doi.org/10.1097/00005392-200102000-00016 CrossRefPubMed

53.

Lambert E, Dasse E, Haye B, Petitfrere E (2004) TIMPs as multifacial proteins. Crit Rev Oncol/Hematol 49(3):187–198. https://doi.org/10.1016/j.critrevonc.2003.09.008 CrossRef

54.

Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF (2005) Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 65(4):645–648. https://doi.org/10.1016/j.urology.2005.01.010 CrossRefPubMed

55.

Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Investig 117(12):3810–3820. https://doi.org/10.1172/jci30487 CrossRefPubMed

56.

Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C (2001) Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276(42):38527–38535. https://doi.org/10.1074/jbc.M104536200 CrossRefPubMed

57.

Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J (2010) NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 65(8):733–738. https://doi.org/10.1136/thx.2009.113456 CrossRefPubMedPubMedCentral

58.

Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernandez-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W, Fabregat I (2012) NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One 7(9):e45285. https://doi.org/10.1371/journal.pone.0045285 CrossRefPubMedPubMedCentral

59.

Poli G, Parola M (1997) Oxidative damage and fibrogenesis. Free Radic Biol Med 22(1–2):287–305CrossRef

60.

Paulis G, Romano G, Paulis L, Barletta D (2017) Recent pathophysiological aspects of Peyronie’s disease: role of free radicals, rationale, and therapeutic implications for antioxidant treatment-literature review. Adv Urol 2017:4653512. https://doi.org/10.1155/2017/4653512 CrossRefPubMedPubMedCentral

61.

Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958):577–584. https://doi.org/10.1038/nature02006 CrossRefPubMed

62.

Miyazono K, Kusanagi K, Inoue H (2001) Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187(3):265–276. https://doi.org/10.1002/jcp.1080 CrossRefPubMed

63.

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9(7):964–968. https://doi.org/10.1038/nm888 CrossRefPubMed

64.

Chen G, Deng C, Li YP (2012) TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 8(2):272–288. https://doi.org/10.7150/ijbs.2929 CrossRefPubMedPubMedCentral

65.

Nohe A, Keating E, Knaus P, Petersen NO (2004) Signal transduction of bone morphogenetic protein receptors. Cell Signal 16(3):291–299CrossRef

66.

Jinnin M (2010) Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 37(1):11–25. https://doi.org/10.1111/j.1346-8138.2009.00738.x CrossRefPubMed

67.

Dolmans GH, Werker PM, de Jong IJ, Nijman RJ, Wijmenga C, Ophoff RA (2012) WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. J Sex Med 9(5):1430–1434. https://doi.org/10.1111/j.1743-6109.2012.02704.x CrossRefPubMed

68.

Kavian N, Servettaz A, Weill B, Batteux F (2012) New insights into the mechanism of notch signalling in fibrosis. Open Rheumatol J 6:96–102. https://doi.org/10.2174/1874312901206010096 CrossRefPubMedPubMedCentral

69.

Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, Beyer C, Zwerina J, Distler O, Schett G, Distler JH (2011) Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 70(7):1304–1310. https://doi.org/10.1136/ard.2010.134742 CrossRefPubMed

70.

Rohatgi R, Milenkovic L, Corcoran RB, Scott MP (2009) Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci USA 106(9):3196–3201. https://doi.org/10.1073/pnas.0813373106 CrossRefPubMed

71.

Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, Zerr P, Avouac J, Gusinde J, Zwerina J, Roudaut H, Traiffort E, Ruat M, Distler O, Schett G, Distler JH (2012) Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 64(8):2724–2733. https://doi.org/10.1002/art.34444 CrossRefPubMed

72.

Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205. https://doi.org/10.1016/j.cell.2012.05.012 CrossRefPubMed

73.

Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, Schett G, Distler JH (2012) beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 71(5):761–767. https://doi.org/10.1136/annrheumdis-2011-200568 CrossRefPubMedPubMedCentral

Titel: A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease
verfasst von: Darshan P. Patel
Michael B. Christensen
James M. Hotaling
Alexander W. Pastuszak
Publikationsdatum: 12.06.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 2/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02815-6

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study

Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond

Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor

Recovery of pad-free continence in elderly men does not differ from younger men undergoing robot-assisted radical prostatectomy for aggressive prostate cancer